Samsara BioCapital’s Palvella Therapeutics PVLA Stock Holding History

Samsara BioCapital’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,432	Closed	-$4.79M	–	26
2026 Q1	$4.79M	Sell	38,432 -66,385	-63%	-$6.92M	0.47%	21
2025 Q4	$11M	Sell	104,817 -104,817	-50%	-$8.94M	1.13%	14
2025 Q3	$13.1M	Sell	209,634 -130,109	-38%	-$5.8M	1.72%	11
2025 Q2	$7.66M	Sell	339,743 -339,743	-50%	-$7.97M	1.57%	10
2025 Q1	$19M	Hold	679,486	–	–	3.39%	6
2024 Q4	$8.15M	Buy	+679,486	New	+$10.7M	1.12%	16
2020 Q3	–	Sell	-20,253	Closed	-$5.2M	–	40
2020 Q2	$5.2M	Hold	20,253	–	–	1.67%	17
2020 Q1	$3.69M	Buy	20,253 +11,450	+130%	+$2.89M	2.13%	14
2019 Q4	$2.55M	Buy	+8,803	New	+$2.44M	1.22%	15

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Samsara BioCapital's PVLA Position: Q2 2026 in Review

Samsara BioCapital sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 38,432 shares — an estimated $4.79M sold.

Samsara BioCapital first reported a position in PVLA in Q4 2019 and held it in 9 quarters. The position peaked at $19M in Q1 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Samsara BioCapital reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
Samsara BioCapital sold 38,432 Palvella Therapeutics shares in Q2 2026, an estimated $4.79M.
Samsara BioCapital first reported a position in Palvella Therapeutics in Q4 2019 and held it in 9 quarters.
Samsara BioCapital's Palvella Therapeutics position peaked at $19M in Q1 2025.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.